Onkologie. 2010:4(5):311-314
The role of pemetrexed in treating lung cancer
- Plicní klinika LF UK a FN Hradec Králové
Pemetrexed represents the first member of the novel class of antifolates – MTA (multitargeted antifolate). Clinical trials have clearly demonstrated
its high efficacy in the treatment of NSCLC, both in the first-line and second-line setting as well as in maintenance therapy, with
a low rate of adverse effects. It is the first cytostatic drug whose efficacy has been shown to be related to the histological type of tumour;
therefore, it is not indicated in patients with squamous-cell NSCLC. Patients receive it during treatment at major cancer centres.
Keywords: pemetrexed, NSCLC, first-line treatment, second-line treatment
Published: December 31, 2010 Show citation
References
- Demlová R, Radina M, Štěrba J, Valík D. Foláty. Fyziologie, metabolismus a mechanismus rezistence na jejich antagonisty. Klin Onkol 2004; 17: 185-189.
- Esteban E, Casillas M, Cassinello A. Pemetrexed in first-line treatment of non-small cell lung cancer. Cancer Treat Rev 2009; 35: 364-373.
Go to original source... 
Go to PubMed... - Baldwin CM, Perry CM. Pemetrexed. A review of its use in management of advanced non-squamous non-small cell lung cancer. Drugs 2009; 69: 2279-2302. Go to original source... Go to PubMed...
- Pemetrexed - souhrn údajů o přípravku. Eli Lilly and Comp., Indianapolis, USA.
- Hanna N, Shepherd FA, Fosella FV, Pereira JR, De Marinis F, von Pawel J, Gatzemeier U, Chang You Tsao T, Pless M, Muller T, Lim HL, Desch Ch, Szondy K, Gervais R, Manegold Ch, Paul S, Paoletti P, Einhorn L, Bunn PA. Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non-SmallCell Lung Cancer Previously Treated With Chemotherapy. J Clin Oncol 2004; 22: 1589-1597. Go to original source... Go to PubMed...
- Peterson P, Park K, Fossella F, Gatzemeier U, John W, Scagliotti G. Is pemetrexed more effective in adenocarcinoma and large cell lung cancer than in squamous cell carcinoma? A retrospective analysis of a phase III trial of pemetrexed vs docetaxel in previously treated patients with advanced non-small cell lung cancer (NSCLC). J Thorac Oncol 2007; 2: S851. Go to original source...
- Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold Ch, Serwatowski P, Gatzemeier U, Digumarti R, Zukin M, Lee JS, Mellemgaard A, Park K, Patil S, Rolski J, Goksel T, de Marinis F, Simms L, Sugarman KP, Gandara D. Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non-Small-Cell Lung Cancer. J Clin Oncol 2008; 26: 3543-3551. Go to original source... Go to PubMed...
- Scagliotti G, Hanna N, Fosella F, Sugarman K, Blatter J, Peterson P, Simms L, Shepherd FA. The differential efficacy od pemetrexed according to NSCLC histology: a review of two phase III studies. The Oncologist 2009; 14: 253-263. Go to original source... Go to PubMed...
- Ciuleanu T, Brodowicz T, Zielinski Ch, Kim JH, Krzakowski M, Laack E, Wu YL, Bover I, Begbie S, Tzekova V, Cucevic B, Pereira JR, Yang SH, Madhavan J, Sugarman KP, Peterson P, John WJ, Krejcy K, Belani ChP. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for nonsmall-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009; 374: 1432-1440. Go to original source... Go to PubMed...
- Rossi A, Ricciardi S, Maione P, de Marinis P, Gridelli C. Pemetrexed in the treatment of advanced non-squamous lung cancer. Lung Cancer 2009; 66: 141-149. Go to original source... Go to PubMed...
- Vogelzang NJ, Rusthoven JJ, Symanovski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21: 2636-2644. Go to original source... Go to PubMed...
- Manegold Ch, Schmid-Bindert G, Pilz LR. Pemetrexed for the treatment of non-small-lung cancer. Expert Rev Anticancer Ther 2009; 9: 1195-1209. Go to original source... Go to PubMed...